Document:

EX-10.1

 Exhibit 10.1 

EMPLOYMENT AND NON-COMPETITION AGREEMENT 

This EMPLOYMENT AND NON-COMPETITION AGREEMENT (this “Agreement”) is effective as of
January 16, 2017 (the “Effective Date”), by and between Addus Healthcare, Inc., an Illinois corporation (the “Company”), and W. Bradley Bickham, an individual domiciled in the State of Texas (the
“Executive”). The Company and Executive are hereinafter sometimes referred to individually as a “Party” and collectively as the “Parties.” 

WHEREAS, the Company, its parent and its subsidiaries (collectively, the “Addus HealthCare Group”) provide home care
services to individuals, county and state governments, health maintenance organizations, independent physician associations, insurance companies, facilities, other business purchasers of such services, and to the general public at large; 

WHEREAS, the Company desires to employ the Executive as its Executive Vice President and Chief Operating Officer, and the Parties
desire to enter this Agreement to secure the Executive’s employment, all on the terms and conditions set forth herein; 

WHEREAS, by virtue of the Executive’s employment by the Company pursuant to the terms hereof, the Executive will obtain and become
familiar with certain valuable confidential and proprietary information relating to the Addus HealthCare Group. 
 NOW, THEREFORE, in
consideration of the mutual covenants and agreements set forth herein, the Parties, intending to be legally bound, agree as follows: 
  

	 	1.	Effectiveness; Term of Employment. 

  

	 	(a)	This Agreement shall automatically become effective on the Effective Date provided the Executive commences employment on such date; otherwise, this Agreement shall automatically terminate on the Effective Date and shall
be deemed never to have become effective. 

  

	 	(b)	 The Company hereby employs the Executive, and the Executive hereby accepts employment by the Company for the
period commencing as of the Effective Date and ending on the first (1st) anniversary of the Effective Date, or on such earlier date as provided pursuant to the terms and conditions of this Agreement (the “Initial Employment Term”).
At the end of the Initial Employment Term, this Agreement shall automatically renew for successive one (1) year terms (each, as may be earlier terminated pursuant to the terms and conditions of this Agreement, an “Additional Employment
Term” and together with the Initial Employment Term, the “Employment Term”), unless either Party provides notice to the other of its or his intention not to renew this Agreement at least thirty (30) days prior to the
expiration of the Initial Employment Term or any Additional Employment Term (a “Non-Renewal”). During the Employment Term, the Executive shall (i) devote substantially all of his
professional time, loyalty, and efforts to discharge his duties hereunder on 

  
 1 

	 	
a timely basis; (ii) use his best efforts to loyally and diligently serve the business and affairs of the Addus HealthCare Group; and (iii) endeavor in all respects to promote, advance,
and further the Addus HealthCare Group’s interests in all matters. To the extent it does not interfere with Executive’s duties hereunder in any material respect, the Parties agree that this provision should not be construed as limiting
Executive’s right to serve on up to one (1) board of, or otherwise engage in activities on behalf of, charitable and civic organizations and, upon prior written approval of the Company, one (1) board of a for profit entity that does
not compete with the business of the Company. 

  

	 	2.	Employment Duties. 

 During the Employment Term, the Company will employ the
Executive as its Executive Vice President and Chief Operating Officer, a senior executive position that reports directly to the Chief Executive Officer (“CEO”) of the Company. The Executive’s principal duties and
responsibilities shall be to oversee and direct the operations of the Addus HealthCare Group including the management and delivery of home care and adult day care services and the performance of such other executive duties and responsibilities as
may be assigned to him by the CEO or the Board of Directors and are consistent with the Executive’s position as Chief Operating Officer of the Company. 
  

	 	3.	Compensation. 

 The Company will pay the Executive as follows during the
Employment Term: 
  

	 	(a)	Base Salary. Commencing on the Effective Date of this Agreement, the Company shall pay the Executive a base salary at the annual rate of Three Hundred Fifty Thousand Dollars ($350,000), which shall
be paid in accordance with the normal payroll practices of the Company and shall be subject to applicable withholdings and deductions. Thereafter, the Executive’s base salary shall be subject to review and adjustment upward by the compensation
committee (the “Compensation Committee”) of the board of directors of Addus HomeCare Corporation (“Addus HomeCare”) (the “Board of Directors”) on or about each anniversary of the Effective Date for
each year during the Employment Term (as adjusted from time-to-time, the “Base Salary”). 

 

	 	(b)	 Bonus. The Executive, at the discretion of the Compensation Committee, shall be eligible
(but not entitled) to receive an annual bonus as set forth on Exhibit A hereto. The Compensation Committee, at its sole discretion, may determine the amount of the annual bonus, if any, to which the Executive may become entitled based on the
quantitative and qualitative factors described on Exhibit A or any other factors the Compensation Committee may deem appropriate from time to time. All amounts payable pursuant to this Section 3(b), if any, shall be paid within no more than
thirty (30) days after completion of Addus HomeCare’s audited financial statements for the most recently completed fiscal year and shall 

  
 2 

	 	
be subject to applicable withholdings and deductions. Bonus is not salary and is earned on the day it is paid. To be eligible to receive the bonus, the Executive must be actively employed and
must not have given notice of termination on or prior to such date. 

  

	 	(c)	Equity Awards. On or as soon as practicable following the Effective Date, the Executive will be granted (i) a nonqualified stock option pursuant to Addus HomeCare’s 2009 Stock Incentive
Plan (the “Plan”) to purchase 50,000 shares of Addus HomeCare’s common stock (“Common Stock”), pursuant to a Nonqualified Stock Option Award Agreement to be entered into by the Executive and Addus HomeCare, and
(ii) 10,000 restricted shares of Common Stock under the Plan pursuant to a Restricted Stock Award Agreement to be entered into by the Executive and Addus HomeCare. The equity awards will vest annually over a four-year period and will be subject to
such other terms and conditions set forth in the Plan and applicable award agreements. 

  

	 	4.	Expenses. 

 It is recognized that the Executive, in the performance of his duties
hereunder, may be required to expend sums for travel (e.g., airfare, automobile rental, etc.), entertainment, and lodging. During the Employment Term, the Company shall reimburse the Executive for reasonable business expenses incurred by him during
the Employment Term in connection with the performance of his duties hereunder conditioned upon and subject to the Company’s established policies and procedures, including written receipt from the Executive of an itemized accounting in
accordance with the Company’s regular business expense verification practices. 
  

	 	5.	Benefits. 

 During the Employment Term, the Executive shall be entitled to
benefits under such plans, programs, or arrangements as the Board of Directors may establish or maintain from time to time for similarly-situated employees, and in accordance with its policies, which may change at the sole discretion of the Board of
Directors. Benefits as of the Effective Date are: 
  

	 	(a)	Four (4) weeks of paid vacation during each year of employment. Subject to the Company’s established policies and procedures, vacation may be carried over to a subsequent year of employment, not to exceed
eight (8) weeks during any calendar year of employment. 

  

	 	(b)	Five (5) days personal/sick leave per year, with pay. Personal/sick days may be carried over to a subsequent year of employment, not to exceed ten (10) days during any calendar year of employment.

  

	 	(c)	Six (6) Company holidays, plus two (2) floating holidays, per year. 

  

	 	(d)	 Coverage beginning on the Effective Date under the health benefit plan provided by the Company to its executives,
which may change, at the sole discretion of the 

  
 3 

	 	
Board of Directors, from time to time. The Company will cover the Executive and his dependents, if any, during the Employment Term to the same extent and according to the same terms as the
Company’s other executives are covered. 

  

	 	(e)	Life insurance policy beginning on the Effective Date with a face amount of up to five (5) times the Base Salary, provided that the Company shall not be required to spend greater than three percent (3%) of the Base
Salary in purchasing such insurance policy. 

  

	 	(f)	Short-term and long-term disability insurance beginning on the Effective Date to the same extent and according to the same terms as the Company’s other similarly-situated executives are covered, which may change,
at the sole discretion of the Board of Directors, from time to time. 

  

	 	(g)	Tuition reimbursement shall be available for courses relevant to the Executive’s position and taken at an accredited institution, subject to prior approval by the Board of Directors. 

 

	 	(h)	Participation in the Company’s 401(k) plan up to the defined Internal Revenue Service limit beginning 30 days after the Effective Date. The Company will annually match 6% of the Executive’s annual contribution
to such plan during the Employment Term, subject to the Company’s established policies and procedures. 

  

	 	6.	Termination by the Company. 

  

	 	(a)	The Company may terminate the Executive’s employment hereunder at any time for Reasonable Cause. The term “Reasonable Cause” shall be limited to the following: 

(i) A material breach or omission by the Executive of any of his duties or obligations under this Agreement (except due to Disability, as
defined below) that the Executive shall fail to cure after receipt of written notice of such breach or omission from the Company’s CEO or Board of Directors, which notice shall designate a reasonable period of time, if curable at all, of not
less than ten (10) business days within which the breach or omission must be cured to the reasonable satisfaction of the CEO or the Board of Directors, as applicable, in order to prevent a termination for Reasonable Cause; provided,
however, that the Executive shall only be permitted the opportunity to cure such breaches or omissions a total of two times in any twelve (12)-month rolling period; 

(ii) Willfully engaging in any action that materially damages, or that may reasonably be expected to materially damage, the Addus HealthCare
Group or the business or goodwill thereof; 

  
 4 

 (iii) Breaching the Executive’s fiduciary duty to the Addus HealthCare Group; 

(iv) Committing any act involving fraud, misusing or misappropriating money or other property of the Addus HealthCare Group, committing a
felony, using illegal drugs, misusing or abusing prescriptive or over-the-counter drugs, habitually using other intoxicants, or chronic absenteeism; 

(v) Gross negligence or willful misconduct by the Executive; 

(vi) Committing acts constituting gross insubordination, such as, without limitation, the intentional disregard of any reasonable directive of
the CEO or the Board of Directors; or 
 (vii) failing to perform any material duty in a timely and effective manner and failing to cure any
such performance deficiency after receipt of written notice of the deficiency from the CEO or Board of Directors, which notice shall designate the reasonable period of time, if curable at all, of not less than ten (10) days within which the
performance deficiency must be cured to the reasonable satisfaction of the CEO or the Board of Directors, as applicable, in order to prevent a termination for reasonable cause; provided, however, that the Executive shall only be
permitted the opportunity to cure such performance deficiencies a total of two times in any twelve (12)-month rolling period. 
  

	 	(b)	The Executive’s employment hereunder shall be terminated in the event of his death, and the Company may terminate the Executive’s employment hereunder if the Executive suffers a physical or mental disability
(a “Disability”) so that the Executive is or, in the opinion of an independent physician retained by the Company for purposes of this determination will be, unable to perform his duties in a manner satisfactory to the Company for a
period of ninety (90) days out of any one hundred eighty (180) consecutive-day period (in which event the Executive shall be deemed to have suffered a permanent Disability). 

 

	 	(c)	The Company may terminate the Executive’s employment hereunder at any time for any other reason, or for no reason. 

  

	 	(d)	Termination of the Executive’s employment for any reason shall terminate the Employment Term but shall not affect the Executive’s obligations pursuant to Section 9 hereof, which obligations shall remain
in effect for the period therein provided. 

  

	 	7.	Termination by the Executive. 

 The Executive may terminate his employment with
the Company (a) for Good Reason (as defined below) or (b) without Good Reason, in each case, upon not less than thirty (30) days 

  
 5 

 
prior written notice to the Company; provided, however, that after the receipt of such notice, the Company may, in its discretion accelerate the effective date of such termination at
any time by written notice to the Executive. Termination of the Executive’s employment by the Executive shall terminate the Employment Term but shall not affect the Executive’s obligations under Section 9 hereof, which obligations
shall remain in effect for the period therein provided. As used herein, “Good Reason” means (i) any reduction in the Executive’s Base Salary, (ii) any material reduction to the Executive’s employment duties and
responsibilities, (iii) any material breach by the Company of any material term of this Agreement, other than a breach which is remedied by the Company within 10 days after receipt of written notice given by the Executive, (iv) a change in
the Executive’s direct reporting duty to a person other than the CEO of the Company or the Board of Directors; or (v) the relocation of the Executive’s principal office to a location more than fifty (50) miles from Frisco, Texas.

  

	 	8.	Rights and Obligations Upon Termination. 

  

	 	(a)	If the Executive’s employment is terminated by the Company pursuant to Section 6(a) or 6(b) hereof or by the Executive pursuant to Section 7(b) hereof, the Executive or his estate shall have no further rights
against the Addus HealthCare Group hereunder, except for the right to receive, with respect to the period prior to the effective date of termination: 

(i) Any unpaid Base Salary under Section 3(a) hereof for any period prior to the effective date of termination; 

(ii) Any accrued but unpaid benefits under Section 5 hereof for any period prior to the effective date of termination; and 

(iii) In the case of termination pursuant to Section 6(b), eligibility for life or disability insurance benefits described in Sections
5(e) or (f), as applicable. 
 Such payments shall be made to the Executive whether or not the Company chooses to utilize the services of the
Executive for the required notice period specified in Section 7. 
  

	 	(b)	If the Executive’s employment is terminated pursuant to Section 6(c) hereof or Section 7(a) hereof, or as a result of Non-Renewal by the Company, the Executive shall be
entitled to, in lieu of any further payments to the Executive for periods subsequent to the date of termination: 

 (i) Any
unpaid Base Salary under Section 3(a) hereof for any period prior to the effective date of termination; 
 (ii) A pro rata portion of
the bonus under Section 3(b) hereof based on what Executive would have been entitled to receive pursuant to the Company’s then-effective bonus plan had his employment not been 

  
 6 

 
terminated, which shall be payable following the time the Company determines the amount of bonuses payable to its executives following the end of the year in which termination occurs; 

(iii) Any accrued but unpaid benefits under Section 5 hereof for any period prior to the effective date of termination; 

(iv) Conditioned upon the Executive’s strict compliance with the post-employment restrictions described in Section 9 below and
subject to applicable withholdings and deductions, severance pay (“Base Severance Pay”) in an amount equal to the Executive’s Base Cash Compensation (as defined below) to be paid in equal installments on the Company’s
regular pay dates over the twelve (12) month period following termination of the Executive’s employment (subject to applicable withholdings and deductions, plus, if the Executive elects to continue his health, dental, and/or vision
insurance coverage under COBRA, the Executive shall be eligible to receive cash payments equal to the difference between his COBRA continuation coverage premiums and the amount of premiums paid by similarly-situated active employees of the Company
under the Company’s health, dental, and/or vision insurance plans, for a period of twelve (12) months following the Executive’s date of termination of employment, to be paid in equal installments on the Company’s regular pay
dates (subject to applicable withholdings and deductions). 
 For purposes of this Agreement, “Base Cash Compensation”
shall mean the highest annual Base Salary in effect for the Executive. 
  

	 	(c)	 Notwithstanding anything to the contrary set forth herein, if the Executive’s employment is terminated by
the Company pursuant to Section 6(c) within six (6) months prior to, or one (1) year following, a Change in Control (as defined below), the Executive shall be entitled to, in lieu of the payments to be made pursuant to Section 8(b)(iv), an
amount equal to the Executive’s Annual Cash Compensation (as defined below) (subject to applicable withholdings and deductions, less any payment already received pursuant to Section 8(b)(iv) (“Change of Control Severance Pay”
and, together with Base Severance Pay, “Severance Pay”), which shall be payable in accordance with the normal payroll practices of the Company in equal installments on the Company’s regular pay dates for one (1) year
following termination of the Executive’s employment, plus, if the Executive elects to continue his health, dental and/or vision insurance coverage under COBRA, the Executive shall be eligible to receive cash payments equal to the difference
between his COBRA continuation coverage premiums and the amount of premiums paid by similarly-situated active employees of the Company under the Company’s health, dental and/or vision insurance plans, payable in equal installments on the
Company’s regular pay dates (subject to applicable withholdings and deductions) until the earlier of (x) one (1) year following the termination of the Executive’s employment or (y) the date that the

  
 7 

	 	
Executive is eligible to receive coverage and benefits from a new employer. As used herein, a “Change in Control” shall be deemed to have occurred if (i) any
“person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), other than a trustee or other fiduciary holding securities under an employee benefit plan
of Addus HomeCare, or a corporation owned directly or indirectly by the stockholders of Addus HomeCare in substantially the same proportions as their ownership of stock of Addus HomeCare, becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of Addus HomeCare representing more than 50% of the total voting power represented by Addus HomeCare’s then outstanding securities that vote
generally in the election of directors (referred to herein as “Voting Securities”); or (ii) after the date of this Agreement, the stockholders of Addus HomeCare approve (x) a merger or consolidation of Addus HomeCare with any
other corporation, other than a merger or consolidation that would result in the Voting Securities of Addus HomeCare outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into Voting
Securities of the surviving entity) more than 50% of the total voting power represented by the Voting Securities of Addus HomeCare or such surviving entity outstanding immediately after such merger or consolidation, or (y) a plan of complete
liquidation of Addus HomeCare or an agreement for the sale or disposition by Addus HomeCare of (in one transaction or a series of transactions) all or substantially all of Addus HomeCare’s assets. 

For purposes of this Agreement, “Annual Cash Compensation” shall mean the sum of (a) the highest annual Base Salary in
effect for the Executive and (b) the greater of (i) the Executive’s bonus for the most recently-completed year, if any, or (ii) the annualized amount of the Executive’s target bonus for the then current year. 

 

	 	(d)	The Executive acknowledges and agrees that the Company’s obligations to make payments pursuant to Sections 8(b)(iv) and 8(c) above are expressly conditioned on the Executive timely executing, delivering and not
revoking a customary general release in form and substance satisfactory to the Company within the period that is sixty (60) days following the date of the Executive’s termination of employment or service with the Company. To the extent
that such sixty (60) day period spans two (2) calendar years, no payment of any severance amount or benefit that is (i) considered to be nonqualified deferred compensation within the meaning of Section 409A of the Internal
Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (collectively, “Code §409A”) and (ii) conditioned upon the release, shall be made before the first day of the second calendar year,
regardless of when the release is actually executed and returned to the Company. 

  
 8 

	 	9.	Covenants of the Executive. 

  

	 	(a)	No Conflicts. The Executive represents and warrants that he is not personally subject to any agreement, order, or decree that restricts his acceptance of this Agreement and performance of his duties
with the Company hereunder. 

  

	 	(b)	Non-Competition; Non-Solicitation. During the Employment Term and during the Restrictive Period (as defined below),
the Executive shall not, without the prior written consent of the Company, directly or indirectly, in any capacity whatsoever, either on his own behalf or on behalf of any other person or entity whom he may manage, control, participate in, consult
with, render services for, or be employed by or associated with, compete with the Business (as defined below) in any of the following described manners: 

(i) Engage in, assist, or have any interest in, as principal, consultant, advisor, agent, financier, or employee, any business entity that is,
or that is about to become engaged in, providing goods or services in competition with the Addus HealthCare Group within a geographic radius of fifty (50) miles from any Addus HealthCare Group branch office; 

(ii) Solicit or accept any business (or help any other person solicit or accept any business) from any person or entity that on the Effective
Date is a customer of the Addus HealthCare Group, or during the Employment Term becomes a customer of the Addus HealthCare Group, other than a customer that does not engage in the Business; 

(iii) Induce or attempt to induce any employee of the Addus HealthCare Group to terminate such employee’s relationship with the Addus
HealthCare Group or in any way interfere with the relationship between the Addus HealthCare Group and any employee thereof; or 
 (iv)
Induce or attempt to induce any customer, referral source, supplier, vendor, licensee, or other business relation of the Addus HealthCare Group to cease doing business with the Addus HealthCare Group, or in any way interfere with the relationship
between any such customer, referral source, supplier, vendor, licensee, or business relation, on the one hand, and the Addus HealthCare Group, on the other hand. 

For purposes hereof, the term “Business” means the business of providing home care services of the type and nature that the
Addus HealthCare Group performs and/or any other business activity in which the Addus HealthCare Group performs, or program or service under active development proposed to be performed, and/or any other business activity in which the Addus
HealthCare Group becomes engaged in on or after the date hereof while the Executive is employed by the Company. 
 For purposes hereof, the
term “Restricted Period” means the period beginning on the date on which the Executive’s employment is terminated by the Company or the Executive for any reason and ending on the first (1st) anniversary of such date. 

  
 9 

 Notwithstanding the foregoing provisions, nothing herein shall prohibit the Executive from owning
one percent (1%) or less of any securities of an Addus HealthCare Group competitor, if such securities are listed on a nationally recognized securities exchange or traded
over-the-counter. If, at the time of enforcement of this Section 9(b), a court holds that the restrictions stated herein are unreasonable under the circumstances
then existing, the Parties agree that the maximum period, scope or geographic area reasonable under such circumstances shall be substituted for the stated period, scope or area determined to be reasonable under the circumstances by such court. 

 

	 	(c)	 Non-Disclosure. The Executive recognizes and
acknowledges that he will have access to certain confidential and proprietary information of Addus HealthCare Group, including, but not limited to, Trade Secrets (as defined below) and other proprietary commercial information, and that such
information constitutes valuable, special, and unique property of Addus HealthCare Group. The Executive agrees that he will not, for any reason or purpose whatsoever, except in the performance of his duties hereunder, or as required by law, disclose
any of such confidential information to any person, entity, or governmental authority without express authorization of the Company. This restriction shall not, however, prohibit the Executive from communicating with any Government Agency or
otherwise participating in any investigation or proceeding that may be conducted by any Government Agency, including providing Company documents or other information, without consent of the Company. The Executive further agrees that he shall not, at
any time during the Employment Term or thereafter, without the express prior written consent of the Company, directly or indirectly, in any capacity whatsoever, either on his own behalf or on behalf of any other person or entity that he manages,
controls, participates in, consults with, renders services for, or is employed by or associated with, disclose or use, except when necessary to further the interests of the Business, any Trade Secret of the Addus HealthCare Group, whether such Trade
Secret is in the Executive’s memory or embodied in writing or other physical form. For purposes of this Agreement, “Trade Secret” means any information, not generally known to, and not readily ascertainable by proper means by,
other persons who can obtain economic value from its disclosure or use and is the subject of efforts to maintain its secrecy that are reasonable under the circumstances, including, but not limited to, (i) trade secrets; (ii) information
concerning the business or affairs of the Addus HealthCare Group, including its products or services, fees, costs, and pricing structures, charts, manuals and documentation, databases, accounting and business models, designs, analyses, drawings,
photographs and reports, computer software, copyrightable works, inventions, devices, new developments, methods and processes, whether patentable or unpatentable and whether or not reduced to practice, sales records, and other proprietary commercial
information; (iii) information concerning actual and prospective clients and customers of the 

  
 10 

	 	
Addus HealthCare Group, including client and customer lists and other compilations; and (iv) information concerning employees, contractors, and vendors of the Addus HealthCare Group,
including personal information and information concerning the compensation or other terms of employment of such individuals. “Trade Secret,” however, shall not include general
“know-how” information acquired by the Executive during the course of his employment that could have been obtained by him from public sources without the expenditure of significant time, effort, and
expense. 

  

	 	(d)	Covenant Regarding Confidential and Proprietary Information. The Executive will promptly disclose in writing to the Company each improvement, discovery, idea, invention, and each proposed
publication of any kind whatsoever, relating to the Business made or conceived by the Executive either alone or in conjunction with others while employed hereunder if such improvement, discovery, idea, invention, or publication results from or was
suggested by such employment (whether or not patentable and whether or not made or conceived at the request of or upon the suggestion of the Company, and whether or not during his usual hours of work, whether in or about the premises of the Addus
HealthCare Group and whether prior or subsequent to the execution hereof). The Executive will not disclose any such improvement, discovery, idea, invention or publication to any person, entity, or governmental authority, except to the Company. Each
such improvement, discovery, idea, invention, and publication shall be the sole and exclusive property of, and is hereby assigned by the Executive to, the Company, and at the request of the Company, the Executive will assist and cooperate with the
Company and any person or entity from time to time designated by the Company to obtain for the Company or its designee the grant of any letters patent in the United States of America and/or such other country or countries as may be designated by the
Company, covering any such improvement, discovery, idea, invention, or publication and will in connection therewith execute such applications, statements, assignments, or other documents, furnish such information and data, and take all such other
action (including, without limitation, the giving of testimony) as the Company may from time to time reasonably request. The foregoing provisions of this Section 9(d) shall not apply to any improvement, discovery, idea, invention, or publication for
which no equipment, supplies, facilities, or confidential and proprietary information of Addus HealthCare Group was used and that was developed entirely on the Executive’s own time, unless (x) the improvement, discovery, idea, invention,
or publication relates to the Business or the actual or demonstrably anticipated research or development of the Business, or (y) the improvement, discovery, idea, invention, or publication results from any work performed by the Executive for
the Addus HealthCare Group. 

  

	 	(e)	Non-Disparagement. The Executive agrees that, during the Employment Term and the Restrictive Period, he will not make any statement, either in writing or
orally, that is communicated publicly or is reasonably likely to be communicated publicly and that is reasonably likely to disparage or otherwise harm the business or reputation of the Addus HealthCare Group, or the reputation of any of its current
or former directors, officers, employees, or stockholders. 

  
 11 

	 	(f)	Return of Documents and Other Property. Upon termination of employment, the Executive shall return all originals and copies of books, records, documents, customer lists, sales materials, tapes,
keys, credit cards, and other tangible property of Addus HealthCare Group within the Executive’s possession or under his control. 

  

	 	(g)	Remedies for Breach. In the event of a breach or threat of a breach of the provisions of this Section 9, the Executive hereby acknowledges that such breach or threat of a breach will cause the
Company to suffer irreparable harm and that the Company shall be entitled to an injunction restraining the Executive from breaching such provisions. The foregoing shall not, however, be construed as prohibiting the Company from having available to
it any other remedy, either at law or in equity, for such breach or threatened breach, including, but not limited to, the immediate cessation of employment and any remaining Severance Pay and benefits pursuant to Section 8, the recovery of
damages from the Executive, and the notification of any employer or prospective employer of the Executive as to the limitations and restrictions contained in this Agreement (without limiting or affecting the Executive’s obligations under the
other paragraphs of this Section 9). In addition, the Executive also expressly acknowledges and agrees that, in addition to the foregoing rights and remedies, the Executive shall reimburse the Company for all attorneys’ fees, costs, and
expenses incurred by Company to enforce the provisions of this Section 9. 

  

	 	(h)	Acknowledgement. The Executive acknowledges that he will be directly and materially involved as a senior executive in all important policy and operational decisions of Addus HealthCare Group. The
Executive further acknowledges that the scope of the foregoing restrictions has been specifically bargained between the Company and the Executive, each being fully informed of all relevant facts. Accordingly, the Executive acknowledges that the
foregoing restrictions of this Section 9 are fair and reasonable, are minimally necessary to protect Addus HealthCare Group, its stockholders, and the public from the unfair competition of the Executive who, as a result of his employment with
the Company, will have had access to the most confidential and important information of Addus HealthCare Group, its Business, and future plans. The Executive furthermore acknowledges that no unreasonable harm or injury will be suffered by him from
enforcement of the covenants contained herein and that he will be able to earn a reasonable livelihood following termination of his employment notwithstanding enforcement of the covenants contained herein. 

 

	 	(i)	 Right of Set Off. In the event of a breach by the Executive of the provisions of this
Agreement, the Company is hereby authorized at any time and from time to time, to the fullest extent permitted by law, and after ten (10) days prior written notice to the Executive, to set-off and apply
any and all amounts at any time held 

  
 12 

	 	
by the Company on behalf of the Executive and all indebtedness at any time owing by the Addus HealthCare Group to the Executive against any and all of the obligations of the Executive now or
hereafter existing. 

  

	 	10.	Prior Agreement. 

 This Agreement contains the entire understanding of the Parties
with respect to the matters set forth herein. Each Party acknowledges that there are no warranties, representations, promises, covenants, or understandings of any kind except those that are expressly set forth in this Agreement. This Agreement
supersedes and is in lieu of any and all other agreements between the Executive and the Company or its predecessor or any subsidiary, and any and all such employment agreements or arrangements are hereby terminated and deemed of no further force or
effect. 
  

	 	11.	Assignment. 

 Neither this Agreement, nor any rights or duties of the Executive
hereunder, shall be assignable by the Executive, and any such purported assignment by him shall be void. The Company may assign all or any of its rights hereunder. 
  

	 	12.	Notices. 

 Unless specified in this Agreement, all notices and other
communications hereunder shall be in writing and shall be deemed given upon receipt or refusal thereof if delivered personally, sent by overnight courier service, mailed by registered or certified mail (return receipt requested), postage prepaid, or
emailed to the other Party’s email address on the Company’s computer network (except that email shall not be deemed given upon refusal thereof). Notice to each Party, if mailed or sent by overnight courier service, shall be to the
following addresses: 
  

	 	(a)	If to the Executive, to: 

 W. Bradley Bickham 

613 Swan Drive 
 Coppell, Texas
75019 
  

	 	(b)	If to the Company, to: 

 Addus HealthCare, Inc. 

2300 Warrenville Road 
 Downers
Grove, Illinois 60515 
 Attention: CEO 

With a copy, which shall not constitute notice, to: 

Bass, Berry & Sims 
 150
Third Avenue South 
 Nashville, Tennessee 37201 

Attention: Kris Kemp, Esq. 

Telephone: (615) 742-6237 

E-mail: kkemp@bassberry.com 

Any Party may change its address for notice by giving all other Parties notice of such change pursuant to this Section 12. 

  
 13 

	 	13.	Amendment. 

 This Agreement may not be changed, modified, or amended except in
writing signed by both Parties to this Agreement. 
  

	 	14.	Waiver of Breach. 

 The waiver by either Party of the breach of any provision of
this Agreement shall not operate or be construed as a waiver of any subsequent breach by either Party. 
  

	 	15.	Invalidity of Any Provision. 

 The provisions of this Agreement are severable, it
being the intention of the Parties that, should any provision hereof be invalid or unenforceable, such invalidity or enforceability of any provisions shall not affect the remaining provisions hereof, but the same shall remain in full force and
effect as if such invalid or unenforceable provision or provisions were omitted. 
  

	 	16.	409A Compliance. 

 This Agreement is intended to comply with or be exempt from
Code §409A, and accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance with or exempt from Code §409A. If the Executive is a specified employee within the meaning of that term under Code
§409A, then with regard to any payment that is considered non-qualified deferred compensation under Code §409A and payable on account of a separation from service, such payment shall be made on the
date which is the earlier of (i) the expiration of the six (6)-month period measured from the date of such separation from service, and (ii) the date of the Executive’s death (the “Delay Period”) to the extent
required under Code §409A. Upon the expiration of the Delay Period, all payments delayed shall be paid to the Executive in a lump sum, and all remaining payments due under this Agreement shall be paid or provided for in accordance with the
normal payment dates specified herein. To the extent any reimbursements or in-kind benefits under this Agreement constitute non-qualified deferred compensation for
purposes of Code §409A, (i) all such expenses or other reimbursements under this Agreement shall be made on or prior to the last day of the taxable year following the taxable year in which such expenses were incurred by the Executive,
(ii) any right to such reimbursement or in kind benefits is not subject to liquidation or exchange for another benefit, and (iii) no such reimbursement, expenses eligible for reimbursement, or
in-kind benefits provided in any taxable year shall in any way affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable
year. For purposes of Code §409A, the Executive’s right to 

  
 14 

 
receive any installment payment pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. In no event shall any payment under this Agreement
that constitutes non-qualified deferred compensation for purposes of Code §409A be subject to offset, counterclaim, or recoupment by any other amount unless otherwise permitted by Code §409A. 

 

	 	17.	Governing Law. 

 This Agreement shall be governed by, and construed, interpreted,
and enforced in accordance with the laws of the State of Texas as applied to agreements entirely entered into and performed in Texas by Texas residents exclusive of the conflict of laws provisions of any other state. 

 

	 	18.	Survival. 

 Obligations under this Agreement which by their nature would continue
beyond the termination of this Agreement, including without limitation Sections 8 and 9, shall survive termination of this Agreement for any reason. 
  

	 	19.	Arbitration. 

 Except as set forth below, any controversy or claim arising out of
or relating to this Agreement (including, without limitation, as to arbitrability and any disputes with respect to the Executive’s employment with the Company or the termination of such employment), or the breach thereof, shall be settled by
arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association in effect as of the date of filing of the arbitration administered by a person authorized to practice law in the State of Texas and mutually
selected by the Company and the Executive (the “Arbitrator”). If the Company and the Executive are unable to agree upon the Arbitrator within fifteen (15) days, they shall each select an arbitrator within fifteen
(15) days, and the arbitrators selected by the Company and the Executive shall appoint a third arbitrator to act as the Arbitrator within fifteen (15) days (at which point the Arbitrator alone shall judge the controversy or claim). The
arbitration hearing shall commence within ninety (90) calendar days after the Arbitrator is selected, unless the Company and the Executive mutually agree to extend this time period. The arbitration shall take place in Dallas, Texas. The
Arbitrator will have full power to give directions and make such orders as the Arbitrator deems just. Nonetheless, the Arbitrator explicitly shall not have the authority, power, or right to alter, change, amend, modify, add, or subtract from any
provision of this Agreement except pursuant to Section 15. The Arbitrator shall issue a written decision that sets forth the essential findings and conclusions upon which the Arbitrator’s award or decision is based within thirty
(30) days after the conclusion of the arbitration hearing. The agreement to arbitrate will be specifically enforceable. The award rendered by the Arbitrator shall be final and binding (absent fraud or manifest error), and any arbitration award
may be enforced by judgment entered in any court of competent jurisdiction. The Company and the Executive shall each pay one-half (1/2) of the fees of the Arbitrator. Notwithstanding anything set forth
above to the contrary, in the event that the Company seeks injunctive relief and/or specific performance to remedy a breach, evasion, violation, or threatened violation of this Agreement, the Executive irrevocably waives

  
 15 

 
his right, if any, to have any such dispute decided by arbitration or in any jurisdiction or venue other than a state or federal court in the State of Texas. For any such action, the
Executive further irrevocably consents to the personal jurisdiction of the state and federal courts in the State of Texas. 

  
 16 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first written
above. 
  

			
	ADDUS HEALTHCARE, INC.
		
	By:	 	 /s/ R. Dirk Allison

	Name:	 	R. Dirk Allison
	Title:	 	President & Chief Executive Officer
	
	EXECUTIVE
	
	 /s/ W. Bradley Bickham

	W. Bradley Bickham

  
 17 

 Exhibit A 

Bonus 
 The
Executive is eligible to receive a bonus in an amount equal to up to fifty percent (50%) of the Executive’s annual Base Salary during the applicable calendar year (pro-rated for any partial year),
based on the Company’s evaluation of the Executive’s performance compared to established Company and/or individual objectives at the target levels, and up to seventy-five percent (75%) of the Executive’s annual Base Salary for
performance against established objectives at the maximum levels, in each case, at the discretion of the Board of Directors. The Board of Directors shall review and establish the objectives and target levels annually. 

  
 18Exhibit

    
Exhibit 10.2
INTERIM POSITION AND NON-COMPETE AGREEMENT
This Interim Position and Non-Compete Agreement (the “Agreement”) is made and entered into on this 28th day of September, 2016 by and between ConAgra Foods, Inc. (the “Company”) and John Gehring (“you” or “Gehring”), collectively the “Parties” and is effective on September 28, 2016 (the “Effective Date”). As of the Effective Date, this Agreement supersedes the Transition and Non-Competition Agreement between the Company and Gehring dated August 29, 2016 and any previous versions. The Company and Gehring hereby mutually covenant and agree as follows:
 
	
			
	 
	(1)
	Position, Term, Reporting, Location, Schedule.

 
	
			
	 
	a.
	The Company hereby employs Gehring and Gehring hereby accepts employment with the Company as Vice President and interim Chief Financial Officer (“CFO”) of Lamb Weston. Gehring will be employed by ConAgra Foods, Inc. until the last business day immediately preceding the completion of the Lamb Weston spin off (the date on which the completion occurs, the “Spin-Off Date”), subject to earlier termination in accordance with Section 3 of the Agreement. Effective as of the last business day immediately preceding the Spin-Off Date (the “Transfer Date”), Gehring will be employed by Lamb Weston. As Vice President and interim CFO of Lamb Weston, Gehring will have no further formal responsibilities related to the transition of the ConAgra Foods, Inc. Chief Financial Officer role. Gehring shall be the principal financial officer for Lamb Weston.

 
	
			
	 
	b.
	Gehring’s employment under this Agreement shall commence on the Effective Date and shall continue until December 15, 2016, unless terminated on an earlier date in accordance with Section 3 of the Agreement (such period, the “Term”). As used in this Agreement, “Employer” means the Company prior to the Transfer Date and means Lamb Weston on and after the Transfer Date. The occurrence of the Transfer Date or Spin-Off Date after December 15, 2016 shall not extend the Term.

 
	
			
	 
	c.
	Gehring shall report to ConAgra’s Chief Executive Officer, Sean Connolly, until the Spin-Off Date. Effective as of the Spin-Off Date, Gehring shall report to Chief Executive Officer of Lamb Weston, Thomas Werner. Gehring will not have any direct reports until the Lamb Weston Controller commences employment, at which time s/he will report to Gehring.

 
	
			
	 
	d.
	Gehring will be officed in Omaha, Nebraska. Gehring will commute to Boise, Idaho as necessary to perform the duties of his position. Gehring will be entitled to use Company-owned or Lamb-Weston-owned corporate aircraft for his commute or, if corporate aircraft is unavailable, the highest class of service available on the commercial flight of his choice.

 
	
			
	 
	e.
	Gehring will be expected to work 80 percent of his current schedule. The Company will honor Gehring’s family commitments related to his daughter’s college visits. Gehring will be entitled to participate in company-recognized holidays.

 
	
			
	 
	(2)
	Compensation, Benefits and Related Matters

 
	
			
	 
	a.
	Salary. During the Term, the Company shall continue to pay Gehring at the current rate of his base annual salary of Six Hundred Fifty Thousand Dollars ($650,000.00), less applicable taxes and withholdings required by law or deductions authorized by Gehring pursuant to the Company’s normal payroll procedures.

-1-

	
			
	 
	b.
	Benefits. During the Term and prior to the Spin-Off Date, Gehring shall continue to participate in all Company benefit plans, as in effect or amended from time to time, in which he participates as of the date of this Agreement, subject to the terms of such benefit plans; provided that Gehring will not be eligible for new equity grants in the fiscal year 2017 grant cycle. On and after the Spin-Off Date during the Term, except with respect to equity awards, Gehring shall cease active participation in the Company’s benefit plans (including The ConAgra Foods, Inc. Pension Plan for Salaried Employees) and shall be eligible to participate in all Lamb Weston benefit plans, as in effect or amended from time to time, in which officers of Lamb Weston participate. In connection with the spin off of Lamb Weston, the liabilities associated with Gehring’s accounts under the ConAgra Foods, Inc. Amended and Restated Non-Qualified CRISP Plan and the ConAgra Foods, Inc. Amended and Restated Voluntary Deferred Compensation Plan will not be transferred to Lamb Weston or any nonqualified deferred compensation plan of Lamb Weston.

 
	
			
	 
	c.
	Equity Awards. Gehring’s outstanding equity awards granted under any of the ConAgra Foods 2009 Stock Plan, the ConAgra Foods, Inc. 2014 Stock Plan, the ConAgra Foods, Inc. 2008 Performance Share Plan, and or other applicable plans of the Company under which Gehring received an equity award (the “Company Equity Awards”) shall continue in effect under their existing terms until the Spin-Off Date. In connection with the spin off, the Company Equity Awards will be equitably adjusted to reflect the spin off substantially in the manner determined by the Company’s Human Resources Committee, provided that the Company Equity Awards will remain awards under the Company Equity Plans and will not transfer to Lamb Weston equity plans, and provided further that on and after the Spin-Off Date service or employment requirements under the Company Equity Awards will be based on Gehring’s service or employment with Lamb Weston. Where applicable under the terms of the Company Equity Awards, Gehring shall remain eligible for “early retirement” equity award treatment upon his separation from service with Lamb Weston.

 
	
			
	 
	d.
	Annual Bonus. During the Term and prior to the Spin-Off Date, Gehring shall continue to participate in the Company’s FY17 Management Incentive Plan (the “ConAgra MIP”). Gehring’s ConAgra MIP award shall be based on the number of days employed with the Company during FY17 through the Spin-Off Date, and shall be based on a target of 100% of salary actually received from the Company during FY17 and the funded percentage for then-active members of the Company’s senior leadership team (i.e., no individual modifier will be applied to reduce the award). Gehring’s ConAgra MIP award, if earned, shall be payable at the time other ConAgra MIP awards are paid for other eligible participants. On and after the Spin-Off Date during the Term, Gehring shall be eligible to participate in the Lamb Weston FY17 Management Incentive Plan (the “Lamb Weston MIP”). Gehring’s Lamb Weston MIP award shall be based on the number of days employed with Lamb Weston on and after the Spin-Off Date and shall be subject to all other terms of the Lamb Weston MIP.

 
	
			
	 
	(3)
	Termination of Agreement

 
	
			
	 
	a.
	The Employer may terminate this Agreement at any time, by giving written notice of such termination to Gehring, upon one of the following events: (i) the Company decides not to go forward with the spin off of Lamb Weston; (ii) upon a mutually agreed upon date following the identification and onboarding of a permanent Lamb Weston Chief Financial Officer; (iii) the knowing engagement of Gehring in serious misconduct that is monetarily or otherwise materially injurious to the Company or Lamb Weston; (iv) the failure of Gehring to follow any reasonable or lawful directive of the Board of Directors of the Employer; (v) the admission to, conviction of, or entering of a plea of nolo contendere to any felony or any lesser crime involving moral turpitude, fraud, embezzlement or theft by Gehring: (vi) act by Gehring of fraud, embezzlement, theft or intentional misrepresentation in connection with Gehring’s duties or in the course of Gehring’s engagement with the Company or Lamb Weston; (vii) the material breach of any Company or Lamb Weston policies or rules or any provision of this Agreement; and (viii) any breach of Gehring’s fiduciary responsibility to the Company or Lamb Weston. In the event of a termination for one of the above-listed reasons, the Employer shall pay to Gehring the compensation payable to Gehring for the payroll period in which such termination occurs, prorated to the day of termination. A termination of the Agreement for one of the above-listed reasons will not cause Gehring to forfeit any benefits to which he is otherwise entitled to receive after his termination of employment by reason of the terms of such benefits.

 

-2-

	
			
	 
	b.
	Gehring may terminate this Agreement at any time by giving written notice of such termination to the Employer at least thirty (30) days prior to the effective date of such termination; provided, however, that such period may be reduced by the Employer in its sole and absolute discretion. During such period, it is understood Gehring shall continue to perform relevant duties for the Employer and will assist the Employer with transferring Gehring’s responsibilities in an appropriate manner and take such reasonable actions to assure a smooth transition. In the event of a termination by Gehring, the Employer shall pay to Gehring the compensation payable to Gehring for the payroll period in which such termination occurs, prorated to the day of termination.

(4) Gehring shall execute a Release of Claims in the forms of Exhibit A, attached hereto and by this reference incorporated herein (the “Release”). Gehring hereby acknowledges that he shall have up to twenty-one (21) days to consider and execute this Agreement and Release pursuant to the Older Workers Benefit Protection Act. Gehring understands that he may revoke this Agreement and the Release in writing addressed and delivered to the Company c/o William J. Daley, Chief Counsel, Labor, Employment & Compliance, 222 Merchandise Mart Plaza, Suite 13, Chicago, IL 60654 within seven (7) days after the execution of this Agreement and the Release, in which event, this Agreement and the Release will be of no force and effect and Gehring will not be entitled to any of the payments or benefits provided for herein except to the extent he would be entitled to such benefits without this Agreement. The Release shall become effective on the eighth calendar day following the revocation period provided for in this Paragraph 4 (the “Release Effective Date”). As consideration for the Release, the Company will pay Gehring the gross amount of Two Hundred Fifty Thousand Dollars ($250,000.00), less applicable withholdings (“First Payment”), payable within 30 days following Gehring’s execution of the Agreement and Release, and the other payments and benefits set forth in this Agreement.
(5) Subject to the terms of this Agreement, including meeting all obligations of Paragraph 1 and provided that Gehring signs and returns the Release to the Company within the timeframes set forth herein, and does not revoke the Release, and remains in compliance with this Agreement (including the restrictive covenants set forth in Paragraphs 6, 7 and 8), the Company shall pay Gehring, the sum of Four Hundred Thousand Dollars ($400,000.00), less applicable withholdings (“Additional Payments”). As another pre-condition of Gehring being entitled to and paid the Additional Payments, Gehring also agrees that, within 30 days of his separation from service with the Company and Lamb Weston (within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended), the Company will present and Gehring will sign the attached general release (or one substantially in the form, as determined by the Company) provided in Exhibit B to this Agreement. The Additional Payments shall be made in two installments as follows:
 
	
			
	 
	a.
	Two Hundred Thousand Dollars ($200,000.00), less applicable withholdings, six months after his separation from service with the Company and Lamb Weston (within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended).

 
	
			
	 
	b.
	Two Hundred Thousand Dollars ($200,000.00), less applicable withholdings, twelve months after his separation from service with the Company and Lamb Weston (within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended).

Gehring acknowledges that the First Payment combined with the other payments and benefits set forth in this Agreement are more than sufficient consideration for the restrictive covenants set forth in Paragraphs 6, 7 and 8 below, notwithstanding the Additional Payments.
 
(6) Gehring acknowledges that during his employment he has been granted access to the Company’s Confidential Information. This Confidential Information is not generally known to, or readily ascertainable by, the public or the Company’s competitors and gives the Company a competitive advantage. Unauthorized disclosure of this Confidential Information would result in irreparable injury to the Company, its subsidiaries, affiliates or joint ventures. Gehring therefore shall not, without the Company’s prior permission, directly or indirectly, utilize or disclose to anyone outside of the Company, or permit access by unauthorized persons or entities to, any Confidential Information, and shall take all reasonable precautions to prevent any person or entity access to any of the Confidential Information.
“Confidential Information” is defined as non-public information of value to the Company that Gehring learned in connection with his employment with the Company and that would be valuable to a competitor or other third parties. Confidential Information includes, but is not limited to, information concerning the Company’s business plans, operations, products, services, vendors and vendor contacts, referrals and sourcing, strategies, marketing, sales, inventions, designs, costs, legal strategies, finances, customers, prospective customers, licensees, or licensors; information regarding the Company’s revenue, rates, pricing or price formulas, profit margin; computer software, information received from third parties under confidential conditions; or other valuable financial, commercial, business, technical or marketing information concerning the Company, or any of the products or services made, developed or sold by the Company.

-3-

An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that is made in confidence to a Federal, State, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law. An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal; and does not disclose the trade secret, except pursuant to court order.
(7) Gehring recognizes and agrees that the Company has a legitimate business interest in restricting potential competitors from hiring Employees who possess or otherwise may have or had access to the Company’s or any of its affiliates’ confidential information. Therefore, Gehring agrees that from the date of this Agreement through the twenty-four (24) month period following the Spin Off Date or following the end of the Term, whichever occurs first, Gehring shall not directly or indirectly through any other person or entity recruit, induce, or attempt to induce any Employee to terminate his or his employment with the Company or otherwise interfere in any way with the employment relationship between the Company and its Employees. This restriction includes, but is not limited to: (a) identifying Employees as potential candidates for employment by name, background or qualifications; (b) recruiting or soliciting Employees; and/or (c) participating in any pre-employment interviews with Employees. For purposes of this paragraph “Employee” (including its plural) means any person employed by the Company at the Spin Off Date, The term “Company,” as used in this paragraph, shall include all controlled, direct and indirect, subsidiaries of the Company.
(8) From the date of this Agreement through the twelve (12) month period following the Spin Off Date or following the end of the Term, whichever occurs first (the “Non-Compete Period”), Gehring agrees he will not, within the Restricted Geographic Area, be employed by, work for, consult with, provide services to, or lend assistance to any Competing Organization in a Prohibited Capacity. For purposes of this Agreement:
“Competing Organization” is defined as any organization that researches, develops, manufactures, markets, distributes and/or sells one or more Competing Products/Services.
“Competing Products/Services” means any products, services or activities (including, without limitation, products, services or activities in the planning or development stage during the Non-Compete Period) that compete, directly or indirectly, in whole or in part, with one or more of the material products, services or activities (including, without limitation, products, services or activities in the planning or development stage during the Non-Compete Period) produced, provided, or engaged in by Company or its affiliates at the time of the end of the Term and with which Gehring worked or about which Gehring obtained any trade secret or other Confidential Information at any time during the five (5) years immediately preceding the end of the Term. “Material products, services or activities” means the development, manufacture or production of packaged food products for the retail, foodservice or institutional channels.
 
For purposes of this Agreement, “Prohibited Capacity” is defined as (a) any same or similar capacity to that held by Gehring at any time during the last three (3) years of employment with Company prior to the end of the Term; (b) any executive or managerial capacity; or (c) any capacity in which Gehring’s knowledge of Confidential Information would render his assistance to a Competing Organization a competitive advantage.
For purposes of this Agreement, “Restricted Geographic Area” is defined as all countries, territories, parishes, municipalities and states in which the Company is doing business or is selling its products at the time of the end of the Term, including but not limited to every parish and municipality in the state of Louisiana. Gehring acknowledges that this geographic scope is reasonable given his position with the Company, the international scope of the Company’s business; and the fact that Gehring could compete with the Company from anywhere the Company does business.
(9) Gehring acknowledges that a violation of the restrictive covenants set forth in Paragraphs 6, 7 and 8 above would cause irreparable damage to the Company, and that in the event of a breach or threatened breach, the Company would be entitled to injunctive relief, without the posting of any bond, in addition to any other such relief as may be appropriate at law or in equity.
(10) Gehring shall not be entitled to any other payments or benefits other than as expressly set forth in this Agreement, except those benefits payable pursuant to any pension, equity award, deferred compensation and 401(k) plans of the Company and the agreements related to previously granted equity-based compensation. Except as provided herein, Gehring’s participation in any employee benefit, stock option, or other incentive plan, between Gehring and the Company will continue to vest, be subject to exercise, and/or be forfeited, in each case only as specifically provided for under the terms of any such grants to Gehring and the terms of the applicable plan and relevant agreements.

-4-

(11) Gehring shall make no public statements, or request, cause or solicit any third party to make any public statements that are in any way inconsistent with the terms of this Agreement. Gehring further agrees not to make any disparaging remarks or take any action now, or at any time in the future, that could be detrimental to the reputation of the Company, or any of its directors, officers or employees. Nothing in this Agreement, however, shall prohibit Gehring from providing accurate and truthful information to any court or governmental entity; or to any person or organization in response to legal process or otherwise as required by law or administrative agency process; or making other disclosures that are protected under the whistleblower provisions of federal law or regulation. Neither does this Agreement require Gehring to withdraw, or prohibit Gehring from filing or participating in any investigation by or proceeding with any government administrative agency (such as the EEOC). However, Gehring waives any relief, damages, or remedy as a result of any legal action against the Company based upon the matters released and waived by the Release whether Gehring or another party initiates the action. The Company agrees that Sean Connolly, Colleen Batcheler, Dave Biegger, Charisse Brock, Brian Davison, Jon Harris, David Marberger, Tom McGough, Darren Serrao and Tom Werner will not publically make or publish any disparaging or negative comments about Gehring; provided, however, that nothing herein prohibits them from providing accurate and truthful information to any court or governmental entity; or to any person or organization in response to legal process or otherwise as required by law or administrative agency process.
(12) Gehring agrees to make himself reasonably available to the Company, and will, for twelve (12) months following the Spin Off Date:
 
	
			
	 
	a.
	Personally provide reasonable assistance and cooperation in providing information for the Company, and its representatives, concerning any ConAgra Foods matter of which Gehring is knowledgeable.

 
	
			
	 
	b.
	Personally provide to the Company, and its representatives, reasonable assistance and cooperation relating to any pending or future lawsuits or claims, about which Gehring are knowledgeable.

 
	
			
	 
	c.
	Promptly notify the Company, in writing, if Gehring receives any request from anyone other than the Company for information regarding any potential claims or proposed litigation against the Company or any of its affiliates.

 
	
			
	 
	d.
	Refrain from providing any information related to any matter, claim or potential litigation against the Company, or its affiliates to any non-Con Agra Foods representatives, without either the Company’s written permission or being required to provide information pursuant to legal process. Nothing in this Agreement prohibits Gehring from reporting possible violations of federal law or regulation to any governmental agency or entity, including but not limited to the Department of Justice, the Securities and Exchange Commission, Congress, and any agency Inspector General, or making other disclosures that are protected under the whistleblower provisions of federal law or regulation. No prior authorization of the Company is necessary to make any such reports or disclosures, and no requirement exists to notify the Company of such reports or disclosures.

 
	
			
	 
	e.
	If required by law to provide sworn testimony on ConAgra Foods or affiliate-related matters, to the extent legally permitted, consult with and, to the extent legally permitted, have ConAgra Foods-designated legal counsel present (in addition to any personal counsel) for such testimony. The Company will be responsible for the costs of Company designated counsel (but not personal counsel). Any testimony will be confined to items about which Gehring has actual knowledge rather than speculation, unless otherwise directed by legal process.

 
	
			
	 
	f.
	Gehring will be reimbursed after an expense statement is received for reasonable travel, food, lodging and similar out-of-pocket expenses required to fulfill the cooperation provisions above.

(13) All payments to be made to Gehring hereunder shall be subject to all applicable taxes, including withholding taxes. Gehring will be responsible for all taxes, of any kind, due under this Agreement.
(14) If any provision of this Agreement is determined by a court of competent jurisdiction to be unenforceable in any respect, then such provision shall be deemed limited and restricted to the maximum extent that the court shall deem the provision to be enforceable, or, in the event that this is not possible, the provision shall be severed and all remaining provisions shall continue in full force and effect.
(15) It is intended that any amounts payable under this Agreement will be exempt from or comply with Section 409A of the Internal Revenue Code of 1986, as amended, and treasury regulations relating thereto (collectively, “Section 409A”), so as 

-5-

not to subject Gehring to the payment of any interest and tax penalty which may be imposed under Section 409A, and this Agreement shall be interpreted and construed accordingly; provided however, that neither the Company nor Lamb Weston shall be responsible for any taxes, penalties, interest or other losses or expenses incurred by Gehring due to any failure to comply with Section 409A. The timing of the payments or benefits provided herein may be modified to so comply with Section 409A. To the extent any payment under this Agreement constitutes deferred compensation within the meaning of Section 409A, all references in this Agreement to Gehring’s separation of employment shall mean a separation from service within the meaning of Section 409A. Each payment under this Agreement as a result of Gehring’s separation from service shall be considered a separate payment for purposes of Section 409A. To the extent that any reimbursement or in-kind benefit provided under this Agreement is nonqualified deferred compensation within the meaning of Section 409A: (i) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during a calendar year may not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year; (ii) the reimbursement of an eligible expense must be made on or before the last day of the calendar year following the calendar year in which the expense was incurred; and (iii) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.
(16) The Company will pay all of Gehring’s reasonable legal expenses incurred in connection with the review/negotiation of this Agreement.
 
(17) Gehring will be an officer of the Company until the completion of the Lamb Weston spin off or end of the Term, whichever occurs first. As an officer of ConAgra, he will be covered by the Company’s director & officer liability insurance. Effective upon the completion of the Lamb Weston spin off, if such spin off occurs during the Term, Gehring will be an officer of Lamb Weston Holdings, Inc., and as an officer of Lamb Weston, he will be covered by Lamb Weston’s director & officer liability insurance.
(18) This Agreement shall be governed by the substantive laws of the State of Illinois. The Company and Gehring agree that any legal action relating to this Agreement shall be commenced and maintained exclusively before any appropriate state court of record in Cook County, Illinois, or the United States District Court for the Northern District of Illinois, Eastern Division, and the parties hereby submit to the jurisdiction of such courts and waive any right to challenge or otherwise object to personal jurisdiction or venue in any action commenced or maintained in such courts.
(19) This Agreement, together with the incorporated releases, constitutes the entire agreement of the parties and supersedes any and all prior agreements and understandings between Gehring and the Company, whether oral or in writing, except with regard to the Plans and/or agreements set forth in Paragraph 10 above. This Agreement may not be revoked, amended, modified or revised except as otherwise provided for in this Agreement or in writing executed by Gehring and a corporate officer of the Company.
IN WITNESS WHEREOF, ConAgra Foods, Inc. and John Gehring have executed this Agreement as of the day and year first above written.
 
	
									
	 
	 
	 
	 
	 
	 
	 
	 
	 

	John Gehring
	 
	 
	  
	ConAgra Foods, Inc.

	 
	 
	 
	 
	 

	By:
	 
	/s/ John Gehring
	 
	 
	  
	By:
	  
	/s/ Charisse Brock

	Date:
	 
	9/27/16
	 
	 
	  
	 
	  
	Date: 9/28/16

 

-6-

EXHIBIT A
RELEASE
In consideration of the benefits provided to John Gehring (“Gehring”) and to be received by Gehring from ConAgra Foods, Inc. (the “Company” or “ConAgra”) as described in the Interim Position and Non-Competition Agreement between the Company and Gehring dated September         , 2016 (the “Agreement”):
 
	
			
	 
	1.
	Claims Released. Gehring, for himself and on behalf of anyone claiming through Gehring including each and all of Gehring’s legal representatives, administrators, executors, heirs, successors and assigns (collectively, the “Gehring Releasors”), does hereby fully, finally and forever release, absolve and discharge the Company and each and all of its legal predecessors, successors, assigns, fiduciaries, parents, subsidiaries, divisions and other affiliates, and each of the foregoing’s respective past, present and future principals, partners, shareholders, directors, officers, employees, agents, consultants, attorneys, trustees, administrators, executors and representatives (collectively, the “Company Released Parties”), of, from and for any and all claims, causes of action, lawsuits, controversies, liabilities, losses, damages, costs, expenses and demands of any nature whatsoever, at law or in equity, whether known or unknown, asserted or unasserted, foreseen or unforeseen, that the Gehring Releasors (or any of them) now have, have ever had, or may have against the Company Released Parties (or any of them) based upon, arising out of, concerning, relating to or resulting from any act, omission, matter, fact, occurrence, transaction, claim, contention, statement or event occurring or existing at any time in the past up to and including the date on which Gehring signs this Release, including, without limitation, (i) all claims arising out of or in any way relating to Gehring’s employment with or separation of employment from the Company or its affiliates; (ii) all claims for compensation or benefits, including salary, commissions, bonuses, vacation pay, expense reimbursements, severance pay, fringe benefits, stock options, restricted stock units or any other ownership interests in the Company Released Parties; (iii) all claims for breach of contract, wrongful termination and breach of the implied covenant of good faith and fair dealing; (iv) all tort claims, including claims for fraud, defamation, invasion of privacy and emotional distress; (v) all other common law claims; and (vi) all claims (including claims for discrimination, harassment, retaliation, attorneys’ fees, expenses or otherwise) that were or could have been asserted by Gehring or on his behalf in any federal, state, or local court, commission, or agency, or under any federal, state, local, employment, services or other law, regulation, ordinance, constitutional provision, executive order or other source of law, including without limitation under any of the following laws, as amended from time to time: the Age Discrimination in Employment Act (the “ADEA”), as amended by the Older Workers’ Benefit Protection Act of 1990 (the “OWBPA”), Title VII of the Civil Rights Act of 1964, 42 U.S.C. §§ 1981 & 1981a, the Americans with Disabilities Act, the Equal Pay Act, the Employee Retirement Income Security Act, the Lilly Ledbetter Fair Pay Act of 2009, the Family and Medical Leave Act, Sarbanes-Oxley Act of 2002, the National Labor Relations Act, the Rehabilitation Act of 1973, the WARN Act, Federal Executive Order 11246, the Genetic Information Nondiscrimination Act, the Illinois Human Rights Act, and the Illinois Wage Payment and Collection Act.

	 
	2.
	Scope of Release. Nothing in this Release (i) shall release the Company from any of its obligations set forth in the Agreement or any claim that by law is non-waivable, (ii) shall release the Company from any obligation to defend and/or indemnify Gehring against any third party claims arising out of any action or inaction by Gehring during the time of his employment and within the scope of his duties with the Company to the extent Gehring has any such defense or indemnification right, and to the extent permitted by applicable law and to the extent the claims are covered by the Company’s director & officer liability insurance or (iii) shall affect Gehring’s right to file a claim for workers’ compensation or unemployment insurance benefits.

Gehring further acknowledges that by signing this Release, Gehring does not waive the right to file a charge against the Company with, communicate with or participate in any investigation by the EEOC or any comparable state or local agency. However, Gehring waives and releases, to the fullest extent legally permissible, all entitlement to any form of monetary relief arising from a charge Gehring or others may file, including without limitation any costs, expenses or attorneys’ fees. Gehring understands that this waiver and release of monetary relief would not affect an enforcement agency’s ability to investigate a charge or to pursue relief on behalf of others.
 

-7-

	
			
	 
	3.
	Knowing and Voluntary ADEA Waiver. In compliance with the requirements of the OWBPA, Gehring acknowledges by his signature below that, with respect to the rights and claims waived and released in this Release under the ADEA, Gehring specifically acknowledges and agrees as follows: (i) Gehring has read and understands the terms of this Release; (ii) Gehring has been advised and hereby is advised, and has had the opportunity, to consult with an attorney before signing this Release; (iii) Gehring is releasing the Company and the other Company Released Parties from, among other things, any claims that Gehring may have against them pursuant to the ADEA; (iv) the releases contained in this Release do not cover rights or claims that may arise after Gehring signs this Release; (v) Gehring has been given a period of twenty-one (21) days in which to consider and execute this Release (although Gehring may elect not to use the full twenty-one (21)-day period at Gehring’s option); (vi) Gehring may revoke this Release during the seven (7) day period following the date on which Gehring signs this Release, and this Release will not become effective and enforceable until the seven (7) day revocation period has expired (the date such revocation period expires, the “Effective Date”); and (vii) any such revocation must be submitted in writing to the Company c/o William J. Daley, Chief Counsel-Labor, Employment & Compliance, Con-Agra Foods, Inc., 222 Merchandise Mart Plaza, Suite 13, Chicago, IL prior to the expiration of such seven (7)-day revocation period. If Gehring revokes this Release within such seven (7)-day revocation period, it shall be null and void.

 
	
			
	 
	4.
	Reaffirmation of Restrictive Covenants. Gehring agrees to and reaffirms his obligations as outlined in Sections 6, 7 and 8 of the Agreement (“Restrictive Covenants”), and acknowledges that the Restrictive Covenants remain in full force and effect.

 
	
			
	 
	5.
	Entire Agreement. This Release, the Agreement, and the documents referenced therein contain the entire agreement between Gehring and the Company, and take priority over any other written or oral understanding or agreement that may have existed in the past. Gehring acknowledges that no other promises or agreements have been offered for this Release (other than those described above) and that no other promises or agreements will be binding unless they are in writing and signed by Gehring and the Company.

I agree to the terms and conditions set forth in this Release.
 
	
			
	 
	 
	 

	JOHN GEHRING

	 

	 

	 

	Date:                                                                                         

 
3

-8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}]]